Cromatic Closes $5.3 Million in Oversubscribed Seed Round to Modernize Life Science R&D Outsourcing

Proprietary outsourcing platform aims to get biotechs off the ground with fast and seamless CRO matching

Cromatic, a full-stack digital platform for outsourced life sciences research, today announced it has closed $5.3 million in funding. LifeX Ventures and AgFunder led the round with participation from Work Life Ventures, Not Boring Capital, FJ Labs, What If Ventures, Lux Capital, and angel investors.

The demand for biotech and pharmaceutical R&D outsourcing is growing rapidly and is expected to be worth $275 billion by 2030. The explosion of biotech in the last decade has seen a doubling of the number of drug candidates under development, with many emerging biotechs outsourcing up to 90% of R&D and operating as “virtual” companies. Across the industry—from small virtual biotechs to large pharma—drug developers are managing R&D costs, addressing capacity constraints, and accessing innovation by outsourcing activities that were historically handled in-house. However, the outsourced R&D service market is highly fragmented and rife with challenges for scientists and procurement departments. Finding the right R&D partner can take months and many projects fail due to poor communication and project management. Cromatic is on a mission to tackle these challenges.

Cromatic’s seamless matching platform helps biotech companies connect with vetted CROs in less than 24 hours. The platform includes a suite of software tools for communication, collaboration, project and management along with a fully integrated payment solution. In the few months since the launch of its platform, Cromatic has over $15 million in R&D budget under management and has established partnerships with leading biotech accelerators, including Nucleate, SOSV, and ValleyDAO. In recognition of its rapid growth, Cromatic was spotlighted as one of the top 40 TechBio companies in Decoding Bio Snapshot 2023.

Ann Lin, co-founder and CEO of Cromatic said, “Outsourcing R&D is one of the most powerful ways for innovative biotech companies to get off the ground. While founders of tech giants like Apple and Google could build their products in garages with minimal resources, founders in biotech are confronted with the capital expense of lab space and equipment and the lengthy process of building the right team before they can even test their ideas. That’s why we are building the most powerful R&D outsourcing platform for biotechs, so that scientists will have clarity, confidence and choice when evaluating and managing their service providers. Ultimately, we want to enable biotech companies to start in garages, just like tech giants.”

“Our mission at Cromatic is deeply rooted in leveraging technology to reshape the landscape of biotech research,” says Anne Chen, Cromatic co-founder and CTO. “By bridging the gap between scientific innovation and efficient outsourcing, we’re not only empowering scientists to bring their ideas to life but also revolutionizing the speed at which life-changing discoveries reach the world. We’re paving the way for a new era of agile and resource-efficient biotech development.”

“We’ve seen incredible growth in the outsourced R&D market, but scientists still spend an inordinate amount of time on administrative tasks rather than value-add experimentation,” said Inaki Berenguer, Managing Partner at LifeX Ventures. “The full stack solution—from matching, contract management, data exchange, project tracking and payments—is the right approach to accelerate and democratize the research process, bringing life-saving drugs faster to market. Ann’s first-hand experience of the struggles to find trusted R&D partners provides a unique perspective and network within the industry. We’re excited to partner with Cromatic as they continue to scale up.”

“The outsourced R&D landscape is a mess,” said Andrew Finkelstein, a VC at AgFunder. “It’s a patchwork of globally hard-to-find specialists, manual workflows, and custom software; and it’s driving up the cost of innovation. Cromatic is spearheading a biotech revolution by bringing outsourced R&D all under one roof with a marketplace of vetted CROs and a suite of project management tools for contracted projects. From crop development and cancer therapeutics to food safety, Cromatic supports the technologies that are reshaping human and planetary health.”

“Big Pharma is increasingly outsourcing innovation to the biotech sector,” said Elliot Hershberg, Biotech Partner at Not Boring. “Now, two out of three drugs that come to market began life in smaller companies. During this transition, there’s been an outpouring of R&D talent into CROs. Cromatic is harnessing this newfound capacity in a coherent platform for a new generation of nimble and capital-efficient biotech companies. We anticipate that in the coming years, real research breakthroughs will happen on Cromatic’s platform.”

This funding round will fast track Cromatic’s product roadmap for biotechs and CROs, forge strategic partnerships and expand its team across product, engineering, sales and customer success.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“The completion of the APEX-AV Study represents an important milestone in the catheter-directed therapies CDT space for the treatment of pulmonary embolism. I sincerely thank all the investigators for their commitment and dedication,” said William Brent Keeling, MD, Associate Professor of Surgery, Department of Surgery, at the Emory University School of Medicine, and Immediate Past President, The PERT Consortium™.
The combined expertise of Cordance Medical and the Airan and Williams Labs will see NeuroAccess utilized to deliver a novel application of drug-loaded nanoparticles, providing targeted drug delivery to the brain.
Medixine prepares for 2024 with two key senior hires, VP of Operations in the U.S. and VP of Engineering in Finland. The appointments will enhance support and service to the company’s U.S.-based partners, including leading respiratory homecare provider Lincare and a major medical device manufacturer. In addition, the new hires will enable streamlined design, testing, and deployment of new product features for more patient-centric, cost and time-effective treatment of chronic conditions.
Innovent Biologics and Synaffix: Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates. Synaffix is eligible to receive an upfront payment plus potentialmilestone payments and royalties on commercial sales for each licensed target.
Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.

By using this website you agree to accept Medical Device News Magazine Privacy Policy